Ono Pharmaceutical has completed the acquisition of Deciphera Pharmaceuticals after a successful tender offer of $25.60 per share, totaling approximately $2.4 billion. The tender offer began on May 13, 2024, and concluded on June 10, 2024, with 88.25% of Deciphera's shares tendered. Upon completion, Deciphera merged into Ono's subsidiary, becoming a wholly-owned entity and delisted from Nasdaq. Ono aims to leverage Deciphera's R&D capabilities and sales networks in oncology to enhance its global expansion. The acquisition is expected to accelerate Ono's pipeline growth and strengthen its position in the global market.
Deciphera Pharmaceuticals announced the Phase 3 results of their MOTION study on vimseltinib for treating tenosynovial giant cell tumor (TGCT) at the 2024 ASCO Annual Meeting and in The Lancet. The study showed significant efficacy, quality-of-life improvements, and a well-tolerated safety profile. The company plans to submit a New Drug Application (NDA) in Q2 2024 and a Marketing Authorization Application (MAA) in Q3 2024. Key findings included a 40% overall response rate (ORR) for vimseltinib compared to 0% for placebo, significant improvements in range of motion, physical function, and pain reduction. Vimseltinib was well tolerated with mainly mild side effects. Additionally, Deciphera is conducting a Phase 1/2 study of DCC-3116 in combination with ripretinib for advanced gastrointestinal stromal tumors, currently in the dose escalation phase.
ONO Pharmaceutical, Co., , is set to acquire Deciphera Pharmaceuticals, Inc. for approximately US $2.4 billion. The deal involves a cash offer of US $25.60 per share, representing a premium of 74.7% to Deciphera's closing share price. The acquisition aims to strengthen ONO's oncology pipeline, expand global reach, and leverage Deciphera's commercial and research capabilities.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.